Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Sponsor: German CLL Study Group
Listed as NCT00281918, this PHASE3 trial focuses on Leukemia and remains completed. Sponsored by German CLL Study Group, it has been updated 9 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- German CLL Study Group
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahaus, Germany , Ansbach, Germany , Auckland, New Zealand , Augsburg, Germany , Bad Saarow, Germany , Bayreuth, Germany , Beersheba, Israel , Berlin, Germany , Bielefeld, Germany , Bietigheim, Germany and 120 more locations